Jeremy B. Hayden has filed a Form 144 to sell 26,000 shares of Sight Sciences, Inc. This transaction, valued at approximately $260,521, is significant as it follows a series of sales earlier this year.

Sight Sciences, Inc., based in Menlo Park, California, operates in the surgical and medical instruments and apparatus sector. The company is publicly traded on NASDAQ under the SEC file number 001-40587.

The filing indicates that Hayden, a former officer of the company, is exercising stock options to acquire the shares. The approximate sale date is noted as November 5, 2026. In the past three months, Hayden has engaged in multiple transactions, selling a total of 92,000 shares.

Hayden's recent activity may affect other stakeholders in Sight Sciences, including current investors and market analysts. The surgical and medical instruments industry remains competitive, and such transactions can influence investor sentiment.

The filing does not say what happens next.

The Form 144 filing indicates that Jeremy B. Hayden is utilizing stock options to acquire the shares, which he plans to sell for cash. The shares being sold are classified as common stock, and the transaction is scheduled for November 5, 2026.

Hayden's recent sales include a significant number of shares, with 92,000 shares sold over the past three months. Notably, these transactions occurred on various dates, including August 11, August 12, and August 14, 2026, with gross proceeds from these sales totaling over $1.1 million. This includes a notable sale of 48,000 shares on August 14, which alone generated approximately $395,880.

The filing also specifies that Hayden's broker for these transactions is Fidelity Brokerage Services LLC, located in Smithfield, Rhode Island. The total number of outstanding shares for Sight Sciences, Inc. is reported to be 55,578,977.

As a former officer of Sight Sciences, Hayden's actions may be closely monitored by investors and analysts, especially in light of the competitive landscape within the surgical and medical instruments sector.

The filing does not provide details on the reasons behind Hayden's decision to sell the shares or his future plans regarding his remaining holdings in the company.